The biopharmaceutical company which is a spin-out from the University of Bath relocates to the North-East of England.
IP Group, a specialist intellectual property investor, has invested £2m ($3.1m) in Glythera, a biopharmaceutical company specialised in protein functionalisation.
The company is a spin-out from the University of Bath. The deal follows an initial £600,000 investment between IP Group and its fund, the Finance for Business North East Technology Fund.
The following two investments are of a similar size and are dependent on certain milestones.
Glythera has also relocated to the North East of England, appointing David Simpson…
